Damian Garde

Biography for Damian Garde

Damian Garde, Editor

Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at dgarde@fiercemarkets.com and follow @DamianFierce on Twitter.

Articles by Damian Garde

Buzz: Cellectis could be in line for a $1.6B Pfizer buyout

Rumor has it the CAR-T specialists at Cellectis are considering a potential sale, and partner Pfizer, already riding its checkbook into the world of immuno-oncology, could be a suitor.

Wall Street's open for biotech business, and Europe is taking notice

Wall Street's recent fervor over biotech companies has hardly been limited to local players, and the allure of handsome valuations and easy access to capital has brought more and more European drug developers across the Atlantic with hopes becoming the next big thing in a boom market.

Atlas' Padlock scoops up some GlaxoSmithKline assets in autoimmunity

Padlock Therapeutics, an Atlas Venture-seeded biotech startup, grabbed the rights to some potential drugs developed by GlaxoSmithKline, widening its arsenal of assets as it chases a novel approach to autoimmune disease.

GlobeImmune's Gilead-partnered hep B vaccine fails in Phase II

GlobeImmune's in-development vaccine for hepatitis B missed the mark in a Phase II trial, marring the value of a program licensed to Gilead Sciences.

Sanofi splurges $245M on Retrophin's speedy-review voucher

Retrophin is selling its recently acquired coupon for a speedy FDA approval to Sanofi for $245 million in cash.

Bluebird widens its CAR-T ambitions with a $130M Five Prime deal

Bluebird bio, already making headlines with its promising gene therapy, is expanding its efforts in immuno-oncology, pairing up with Five Prime Therapeutics to develop cell therapies for cancer.

Sanofi buys into NeuroVive's cardio drug in Korea

Sanofi is betting on the promise of NeuroVive Pharmaceutical's top prospect, buying the South Korean rights to the biotech's Phase III cardiovascular drug.

Boehringer snags FDA approval for COPD combo drug

Boehringer Ingelheim picked up FDA approval for a next-generation COPD treatment, looking to contend for a share of the fast-crowding market for combination therapies.

Amicus' rare disease drug lines up for a quick EU approval

Amicus Therapeutics has landed on the European regulatory fast track, potentially shortening the review time for its orphan drug as it prepares filings at home and abroad.

China's Cellular Biomedicine spikes on early CAR-T data

Shanghai drug developer Cellular Biomedicine reported some positive results from a small study of its in-development cancer immunotherapy, sending its shares up more than 15% on Friday.